UNSPSC 51202407: Dacliximab or daclizumab

This classification denotes a monoclonal antibody and immunosuppressant with the molecular formula C6394H9888N1696O2012S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUJ2MVI71Y, more generally known as daclizumab. European Medicines Agency schedules daclizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06885MIG. The term DACLIZUMAB is an International Non-Proprietary Name or INN. Dacliximab or daclizumab bears US NLM identifiers UMLS ID C0663182 and NCI Concept Code C1569.

Most nations, for tariff and trade purposes, schedule dacliximab or daclizumab under 30021002 and SITC 54163. SMILES: NONE.

UNSPSC 51202407 Dacliximab or daclizumab is a Commodity code for a specific immunosuppressive biologic pharmaceutical, but the recent state and local opportunities posted under this code show negligible alignment with the pharmaceutical itself. The code shows minimal recent activity focused on actual dacliximab procurement; instead, the tagged opportunities span emergency response supplies, direct-to-manufacturer prescription programs, and cooperative purchasing for generic multi-source pharmaceuticals and over-the-counter products. State and local governments use this code inconsistently, and the mismatch between the code's nominal scope and the work actually being solicited suggests either tagging error or that this code functions as a fallback category for broader pharmaceutical and health-supply procurement where more precise commodity codes are not available or were not applied.

The four most recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for naloxone and drug deactivation systems—1,900 units of naloxone and 800 deactivation systems annually with quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for state pharmacy benefit programs. The City of Tampa issued an IFB (26P00145) on March 25, 2026 (due March 13, 2026) for medical and first aid supplies intended for the Tampa Fire Department Rescue Division—an estimated $700,000 contract designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities, including Oregon. Given the minimal genuine activity under the code's actual scope, pursuit of opportunities tagged to this code warrants verification that the specific pharmaceutical or closely related products are what the issuing body is actually seeking.